Press & News

The next generation biopharmaceuticals

Press releases

2018-05-21

Affibody Presents at Anglonordic Life Science

Solna, Sweden, May 21, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced that it is presenting the company at Anglonordic Life Science conference, a UK and Nordic life science conference.[read more]

Older press releases

2018-05-18

Interim Report – January to March 2018

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the first quarter 2018.[read more]

2018-05-11

Affibody Presents at Bio€quity Europe

Solna, Sweden, May 11, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced that it is presenting the company at Bio€quity Europe, an investor and partnering event.[read more]

2018-05-09

Kallelse till årsstämma

Aktieägarna i Affibody Medical AB (publ) kallas härmed till årsstämma onsdagen den 13 juni 2018 klockan 13.00 i bolagets lokaler, Gunnar Asplunds allé 24, Solna.[read more]

Affibodys latest Press releases

2018-12-04

Affibody Announces Option Exercise by Biotest

Solna, Sweden, December 4, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug...[read more]

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

Interim Report Q2 (August 23, 2018)

Investor information